Upharmacia May 2017
PHARMA MARKET NEWS
Gedeon Richter Ukraine Changed Organization Type and Replaced the Management
On May 5, Gedeon Richter Ukraine changed the type of organization from Public JSC to Private JSC. Moreover, the Supervisory Board of the company decided to re-elect the management board of the company. Thus, Natalia Sereda replaced Lazslo Kovach at the position of the Head of the Board.
In 2016, the sales of Gedeon Richter in Ukraine increased 11.3 % y-o-y to EUR 29.6 mio after in 2015, the sales almost halved from EUR 55 mio in 2014. In 2016, the company lost 4 positions in the list of best-selling companies of the Ukrainian retail drug market and held 14th position.
Arterium May Increase Investment in Development
Arterium Corporation may increase investment in development of new preparations by 50-80 % in 2017. In 2016, Arterium invested UAH 106 mio in development. Currently, the Corporation has 80 preparations in development. The key directions of development are cardiology, neurology, gastroenterology and antibacterial agents.
Moreover, Arterium plans to expand the OTC business.
Arterium is implementing the strategy for accessing the EU market. The company has registered medicines in Serbia and plans to access Slovenia. In 2016, Arterium Corporation held second place at the Ukrainian retail drug market climbing two positions as compared to 2015.
Biofarma Disputes the
UNDR Tender
Ukrainian producer of blood preparations Biofarma seeks the UNDR to revise the tender on the procurement of blood factor XVIII, which was won by Italian company Kedrion. The President of Biofarma Kostiantyn Yefymenko stated that the Kedrion’ s bid was 30 % more expensive than the proposition of Biofarma.
“ The MOH has all means to stop the tender and look into situation,” Mr. Yefymenko said.“ We are ready figure this out at any level.” The company appealed to the UNDP for it to cancel the nontransparent decisions. It also requested the MOH of Ukraine to hold a joint meeting with representatives of the UNDP to review the results of the tender and to take measures to prevent similar situations in the future.
Assets of KVF
Increased 71 %
In 2016, the net income of Kyiv Vitamin Factory( KVF) increased 35 % y-o-y to UAH 1.43 bn. The net profit of the company downed to UAH 145 mio form UAH 173 mio in 2015. The value of the company’ s assets increased 71 % y-o-y to UAH 1.09 bn. KVF is among the most dynamically developing companies on Ukrainian pharmaceutical market. In 2016, it was the 9th company on the retail drug market improving the position from 11th place in 2015 and 14th in 2014.
IPMA Signed Memorandum on Cooperation with Indian Pharmexcil
Indian Pharmaceutical Manufacturer’ s Association( IPMA) of Ukraine signed Memorandum on cooperation with the Pharmaceuticals Export Promotion Council of India( Pharmexcil).
“ Our organizations will exchange information and organize joint events to promote the establishment of business relations between Ukraine and India,” the Head of the IPMA said.“ After signing the Memorandum, the Indian company will be able to use organizational
6 www. upharma-c. com